{"gene":"COX5A","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2017,"finding":"A pathogenic variant in COX5A lying within the COX5A/COX4 interface domain reduces complex IV enzymatic activity and protein levels, causes accumulation of the monomeric COX1 assembly intermediate, and disrupts complex IV biogenesis; lentiviral complementation rescues the deficiency, and copper supplementation partially rescues complex IV activity in patient fibroblasts.","method":"Patient fibroblast biochemical assays, lentiviral complementation, structural homology modeling of the COX5A/COX4 interface, copper supplementation rescue experiment","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal protein-level and enzymatic assays in patient cells, lentiviral rescue, assembly intermediate detection, replicated by a second family report (PMID:35246835)","pmids":["28247525"],"is_preprint":false},{"year":2022,"finding":"A second homozygous missense variant (c.266T>G) in COX5A reduces COX5A protein level and complex IV (COX) activity, confirming that biallelic loss-of-function variants in COX5A cause mitochondrial disease with complex IV deficiency.","method":"Clinical exome sequencing, western blotting for COX5A protein, enzymatic assay of COX activity in patient-derived cells","journal":"Clinical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic and protein-level assays in patient cells, single lab, corroborates prior report","pmids":["35246835"],"is_preprint":false},{"year":2014,"finding":"Hypermethylation of the Cox5a promoter in skeletal muscle of high-fat diet rats is associated with reduced Cox5a mRNA and protein, decreased mitochondrial complex IV activity, and lower ATP content; demethylation with 5-aza-2'-deoxycytidine in palmitate-treated myotubes preserves Cox5a expression and restores complex IV activity and ATP levels.","method":"Whole-genome promoter methylation analysis, bisulfite sequencing, qPCR, western blot, complex IV activity assay, ATP measurement, 5-aza-2'-deoxycytidine demethylation experiment in rat myotubes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (methylation sequencing, expression, enzymatic assay, pharmacological rescue), single lab","pmids":["25436770"],"is_preprint":false},{"year":2020,"finding":"COX5A overexpression in transgenic mice improves spatial recognition memory and hippocampal synaptic plasticity and activates the BDNF/ERK1/2 signaling pathway; combined COX5A overexpression with BDNF knockdown abrogates these benefits, placing COX5A upstream of BDNF/ERK1/2 in neuronal function.","method":"COX5A transgenic mice, BDNF knockdown mice, Morris water maze/spatial memory testing, LTP measurement, dendritic morphology analysis, western blot for BDNF/ERK1/2 pathway components, in vitro neuronal growth assays","journal":"Frontiers in aging neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (double transgenic), multiple behavioral and cellular readouts, single lab","pmids":["32754029"],"is_preprint":false},{"year":2020,"finding":"COX5A overexpression in cortical neurons after oxygen-glucose deprivation promotes neuronal survival, reduces apoptosis, increases neurite length, and upregulates Triosephosphate isomerase (TPI); TPI was identified as a physical interaction partner of COX5A by network prediction and validated by western blot.","method":"HSV-mediated COX5A overexpression in OGD neurons, TUNEL/immunofluorescence, western blot, qRT-PCR, GeneMANIA interaction prediction followed by WB validation","journal":"BMC neuroscience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — TPI interaction validated by WB only after computational prediction, single lab, no direct binding assay","pmids":["32349668"],"is_preprint":false},{"year":2023,"finding":"COX5A overexpression in DOX-treated cardiomyocytes and mice restores cytochrome c oxidase activity, ATP content, and mitochondrial morphology, reduces oxidative stress and apoptosis, and activates PI3K/Akt signaling (phosphorylation of Akt Thr308 and Ser473); PI3K inhibitors abrogate the protective effects, placing COX5A upstream of PI3K/Akt.","method":"AAV9/lentivirus-mediated COX5A overexpression in mice and H9c2 cells, echocardiography, transmission electron microscopy, immunofluorescence, COX activity assay, ATP measurement, western blot for PI3K/Akt pathway, PI3K inhibitor rescue experiment","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in vivo and in vitro with pathway inhibitor rescue, single lab","pmids":["37373547"],"is_preprint":false},{"year":2023,"finding":"CLPP inhibition causes accumulation of aggregated/misfolded COX5A, reducing complex IV (oxidative respiratory chain complex IV) content and activity, which leads to ROS accumulation, loss of mitochondrial membrane potential, and activation of the intrinsic apoptotic pathway in human ovarian granulosa cells.","method":"CLPP inhibitor treatment, COX5A overexpression/knockdown in granulosa cells, complex IV activity assay, ROS measurement, mitochondrial membrane potential assay, flow cytometry for apoptosis","journal":"Frontiers in genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assays with multiple orthogonal readouts in relevant human cell line, single lab","pmids":["37007963"],"is_preprint":false},{"year":2023,"finding":"COX5A overexpression in vascular smooth muscle cells (VSMCs) restores PDGF-BB-impaired complex IV activity, oxygen consumption rate, and ATP synthesis while reducing H2O2/ROS production and inhibiting VSMC proliferation and migration; in vivo lentiviral COX5A overexpression attenuates balloon injury-induced neointima formation and mitochondrial ultrastructural damage.","method":"pcDNA3.1-COX5A overexpression and siRNA knockdown in HA-VSMCs, complex IV activity assay, oxygen consumption rate (Seahorse), H2O2/ATP/ROS measurements, cell proliferation/migration assays, lentiviral delivery in rat balloon injury model, carotid morphology and TEM analysis","journal":"Current vascular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods, single lab","pmids":["36924093"],"is_preprint":false},{"year":2020,"finding":"Knockdown of SCN2B in transgenic mice upregulates COX5A mRNA levels and improves hippocampus-dependent spatial memory and LTP, suggesting SCN2B negatively regulates COX5A expression in the context of brain aging.","method":"SCN2B knockdown transgenic mice, Morris water maze, LTP (fEPSP) electrophysiology, qPCR for COX5A mRNA","journal":"Molecular neurobiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — COX5A measured only as mRNA readout in SCN2B-knockdown model, no direct mechanistic interrogation of COX5A, single lab","pmids":["25575679"],"is_preprint":false},{"year":2020,"finding":"miR-204 directly targets and suppresses COX5A expression in ER-positive breast cancer cells; COX5A knockdown decreases ERα expression, causes cell cycle arrest, blocks epithelial-mesenchymal transition, reduces ATP, and increases ROS, thereby inhibiting proliferation, invasion, and enhancing chemosensitivity.","method":"miR-204 overexpression targeting COX5A (in vitro), siRNA knockdown of COX5A in ER+ breast cancer cell lines, ERα western blot, cell cycle flow cytometry, EMT marker analysis, ATP and ROS measurement","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple functional readouts after COX5A manipulation plus miRNA targeting validation, single lab","pmids":["32758616"],"is_preprint":false},{"year":2024,"finding":"In yeast, deletion of COX5A causes hypersensitivity to H2O2; COX5A and NPR3 regulate YAP1 (oxidative stress transcription factor) expression through an alternative mode of translation initiation, linking COX5A to oxidative stress detoxification and antioxidant gene regulation.","method":"Yeast deletion strains, H2O2 sensitivity assays, YAP1 expression analysis, genetic epistasis, translation initiation reporter assays","journal":"FASEB journal","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast model, single lab, novel mechanism of YAP1 regulation via alternative translation initiation not yet validated in mammalian system","pmids":["38416461"],"is_preprint":false},{"year":2026,"finding":"COX5A knockdown in IL-13-stimulated nasal epithelial cells abolishes ROS production and prevents M2 macrophage polarization; COX5A-mediated ROS generation in epithelial cells drives M2 macrophage polarization, and this pathway is confirmed elevated in a murine nasal polyp model.","method":"COX5A siRNA knockdown in IL-13-stimulated epithelial cells, ROS scavenger experiments, flow cytometry for macrophage polarization markers, western blotting, immunofluorescence, murine nasal polyp in vivo model","journal":"Inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — COX5A knockdown with ROS scavenger controls, in vitro and in vivo concordance, single lab","pmids":["41842984"],"is_preprint":false},{"year":2025,"finding":"COX5A enhances mitochondrial oxidative phosphorylation and ATP production in gastric cancer cells, and the resulting elevated ATP activates PI3K/Akt signaling to drive proliferation, migration, and invasion; COX5A silencing suppresses xenograft tumor growth, and PI3K/Akt inhibitors reverse COX5A-mediated effects.","method":"COX5A overexpression/silencing in gastric cancer cell lines, JC-1 mitochondrial membrane potential assay, ATP measurement, western blot for PI3K/Akt, PI3K inhibitor rescue, xenograft mouse model","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in vitro and in vivo with pathway inhibitor rescue, single lab","pmids":["41184196"],"is_preprint":false}],"current_model":"COX5A is a nuclear-encoded structural subunit of mitochondrial respiratory chain complex IV (cytochrome c oxidase) that is required for complex IV biogenesis (acting at the COX5A/COX4 interface) and catalytic activity; loss-of-function causes complex IV deficiency, impaired oxidative phosphorylation, reduced ATP synthesis, and excess ROS, while COX5A overexpression or rescue restores these functions and activates downstream PI3K/Akt and BDNF/ERK1/2 signaling pathways in cardiac, neuronal, vascular, and cancer contexts."},"narrative":{"mechanistic_narrative":"COX5A is a nuclear-encoded structural subunit of mitochondrial respiratory chain complex IV (cytochrome c oxidase) required for complex IV biogenesis and catalytic activity [PMID:28247525]. A pathogenic variant within the COX5A/COX4 interface domain reduces complex IV enzymatic activity and protein levels, causes accumulation of the monomeric COX1 assembly intermediate, and disrupts complex IV assembly, with lentiviral complementation and copper supplementation rescuing the deficiency; a second biallelic missense variant independently confirms that loss-of-function in COX5A causes mitochondrial disease with complex IV deficiency [PMID:28247525, PMID:35246835]. Consistent with this catalytic role, conditions that lower COX5A — promoter hypermethylation, miR-204 targeting, or CLPP-driven misfolding — reduce complex IV activity, ATP content, and mitochondrial membrane potential while elevating ROS, and these are reversed by restoring COX5A expression [PMID:25436770, PMID:37007963, PMID:32758616]. Across cardiac, vascular, neuronal, and cancer contexts, COX5A acts upstream of growth and survival signaling: its overexpression restores cytochrome c oxidase activity and ATP and activates PI3K/Akt signaling to support cardiomyocyte protection, attenuate vascular neointima formation, and drive gastric cancer proliferation and invasion [PMID:37373547, PMID:36924093, PMID:41184196], and it activates BDNF/ERK1/2 signaling to enhance hippocampal synaptic plasticity and spatial memory [PMID:32754029]. COX5A-dependent mitochondrial ROS generation also functions as a signaling output, driving M2 macrophage polarization in IL-13-stimulated nasal epithelium [PMID:41842984].","teleology":[{"year":2017,"claim":"Established that COX5A is a structural subunit essential for complex IV biogenesis and that a human variant at the COX5A/COX4 interface causes complex IV deficiency, defining its disease-causing mechanism.","evidence":"Patient fibroblast enzymatic and protein assays, lentiviral complementation, assembly-intermediate detection, and copper supplementation rescue","pmids":["28247525"],"confidence":"High","gaps":["No high-resolution structure of the human COX5A/COX4 interface within assembled complex IV","Mechanism by which copper supplementation partially rescues activity not defined"]},{"year":2022,"claim":"Confirmed that biallelic loss-of-function variants in COX5A cause mitochondrial disease, generalizing the genotype-phenotype link beyond a single family.","evidence":"Clinical exome sequencing with COX5A western blot and COX enzymatic assay in patient cells","pmids":["35246835"],"confidence":"Medium","gaps":["Single lab corroboration","No functional rescue performed for this variant"]},{"year":2014,"claim":"Showed that COX5A expression is epigenetically regulated and that its loss is sufficient to impair complex IV activity and ATP production, linking metabolic stress to COX5A silencing.","evidence":"Promoter methylation sequencing, expression analysis, complex IV/ATP assays, and 5-aza-deoxycytidine demethylation rescue in high-fat-diet rat muscle and palmitate-treated myotubes","pmids":["25436770"],"confidence":"Medium","gaps":["Rodent/cell model only","Transcription factors mediating methylation-dependent silencing not identified"]},{"year":2020,"claim":"Placed COX5A upstream of BDNF/ERK1/2 signaling in neuronal function, indicating a signaling role beyond bioenergetics in cognition.","evidence":"COX5A transgenic and BDNF-knockdown mice with spatial memory, LTP, dendritic morphology, and pathway western blots","pmids":["32754029"],"confidence":"Medium","gaps":["Molecular link between mitochondrial COX5A and BDNF transcription unresolved","Single lab"]},{"year":2020,"claim":"Identified TPI as a candidate COX5A interaction partner and a neuroprotective effector after ischemic stress.","evidence":"HSV-mediated COX5A overexpression in OGD neurons, computational interaction prediction, and western blot validation","pmids":["32349668"],"confidence":"Low","gaps":["TPI interaction shown by WB only after computational prediction, no direct binding assay","No reciprocal validation"]},{"year":2020,"claim":"Demonstrated that COX5A is a direct miR-204 target and that its loss in ER+ breast cancer suppresses proliferation, EMT, and ERα, connecting COX5A regulation to oncogenic phenotypes.","evidence":"miR-204 targeting, COX5A siRNA, cell cycle, EMT marker, ATP, and ROS analyses in ER+ breast cancer cells","pmids":["32758616"],"confidence":"Medium","gaps":["Mechanism linking COX5A to ERα expression undefined","Single lab"]},{"year":2023,"claim":"Established COX5A as a protective factor upstream of PI3K/Akt in doxorubicin cardiotoxicity, restoring complex IV activity, ATP, and mitochondrial morphology.","evidence":"AAV9/lentiviral COX5A overexpression in mice and H9c2 cells with COX/ATP assays, TEM, and PI3K inhibitor rescue","pmids":["37373547"],"confidence":"Medium","gaps":["Direct molecular link from complex IV/ATP to Akt phosphorylation not defined","Single lab"]},{"year":2023,"claim":"Showed COX5A overexpression restores mitochondrial function in vascular smooth muscle cells and limits neointima formation, extending its protective role to vascular injury.","evidence":"COX5A overexpression/knockdown in HA-VSMCs with Seahorse, COX/ATP/ROS assays, proliferation/migration assays, and rat balloon injury model","pmids":["36924093"],"confidence":"Medium","gaps":["Signaling pathway downstream of restored mitochondrial function in VSMCs not delineated","Single lab"]},{"year":2023,"claim":"Defined COX5A as a target of CLPP-dependent proteostasis whose misfolding/aggregation drives complex IV loss, ROS, and intrinsic apoptosis.","evidence":"CLPP inhibition plus COX5A overexpression/knockdown in human ovarian granulosa cells with complex IV, ROS, membrane potential, and apoptosis assays","pmids":["37007963"],"confidence":"Medium","gaps":["Whether CLPP directly processes COX5A not shown","Single lab"]},{"year":2024,"claim":"Proposed a non-canonical role for COX5A in oxidative stress detoxification via YAP1 regulation through alternative translation initiation in yeast.","evidence":"Yeast deletion strains, H2O2 sensitivity, YAP1 expression, epistasis, and translation initiation reporters","pmids":["38416461"],"confidence":"Low","gaps":["Yeast model only, not validated in mammalian cells","Mechanism of alternative translation initiation regulation unresolved"]},{"year":2025,"claim":"Showed COX5A-driven OXPHOS and ATP activate PI3K/Akt to promote gastric cancer growth, establishing a pro-tumorigenic bioenergetic-signaling axis.","evidence":"COX5A overexpression/silencing in gastric cancer lines with JC-1, ATP assays, PI3K/Akt western blot, inhibitor rescue, and xenografts","pmids":["41184196"],"confidence":"Medium","gaps":["Direct molecular coupling of ATP levels to PI3K/Akt activation undefined","Single lab"]},{"year":2026,"claim":"Demonstrated that COX5A-dependent mitochondrial ROS in nasal epithelium drives M2 macrophage polarization, framing COX5A output as an inflammatory signaling source.","evidence":"COX5A siRNA in IL-13-stimulated epithelial cells with ROS scavenger controls, macrophage polarization flow cytometry, and murine nasal polyp model","pmids":["41842984"],"confidence":"Medium","gaps":["Soluble or contact mediators of epithelium-to-macrophage signaling not identified","Single lab"]},{"year":null,"claim":"How COX5A bioenergetic output is mechanistically transduced into discrete downstream signaling programs (PI3K/Akt, BDNF/ERK1/2, ROS-driven inflammation) across tissues remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No direct molecular link established between complex IV activity/ATP/ROS and the activated kinase cascades","Whether signaling effects are tissue-specific or generalizable is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,5,7]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,5,6,7]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,2,5,7,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,12]}],"complexes":["cytochrome c oxidase (complex IV)"],"partners":["COX4","COX1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P20674","full_name":"Cytochrome c oxidase subunit 5A, mitochondrial","aliases":["Cytochrome c oxidase polypeptide Va"],"length_aa":150,"mass_kda":16.8,"function":"Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over the inner membrane that drives transmembrane transport and the ATP synthase. Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Electrons originating from reduced cytochrome c in the intermembrane space (IMS) are transferred via the dinuclear copper A center (CU(A)) of subunit 2 and heme A of subunit 1 to the active site in subunit 1, a binuclear center (BNC) formed by heme A3 and copper B (CU(B)). The BNC reduces molecular oxygen to 2 water molecules using 4 electrons from cytochrome c in the IMS and 4 protons from the mitochondrial matrix","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/P20674/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/COX5A","classification":"Common Essential","n_dependent_lines":809,"n_total_lines":1208,"dependency_fraction":0.6697019867549668},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ASS1","stoichiometry":0.2},{"gene":"BLVRB","stoichiometry":0.2},{"gene":"CLIP1","stoichiometry":0.2},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"HEATR3","stoichiometry":0.2},{"gene":"PHGDH","stoichiometry":0.2},{"gene":"RAC1","stoichiometry":0.2},{"gene":"RER1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/COX5A","total_profiled":1310},"omim":[{"mim_id":"619064","title":"MITOCHONDRIAL COMPLEX IV DEFICIENCY, NUCLEAR TYPE 20; MC4DN20","url":"https://www.omim.org/entry/619064"},{"mim_id":"617469","title":"AFG1-LIKE ATPase; AFG1L","url":"https://www.omim.org/entry/617469"},{"mim_id":"616500","title":"MITOCHONDRIAL COMPLEX IV DEFICIENCY, NUCLEAR TYPE 9; MC4DN9","url":"https://www.omim.org/entry/616500"},{"mim_id":"613920","title":"CYTOCHROME C OXIDASE ASSEMBLY FACTOR 5; COA5","url":"https://www.omim.org/entry/613920"},{"mim_id":"603774","title":"CYTOCHROME c OXIDASE, SUBUNIT 7C; COX7C","url":"https://www.omim.org/entry/603774"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"heart muscle","ntpm":1666.8},{"tissue":"skeletal muscle","ntpm":1561.5},{"tissue":"tongue","ntpm":1618.5}],"url":"https://www.proteinatlas.org/search/COX5A"},"hgnc":{"alias_symbol":["COX-VA"],"prev_symbol":[]},"alphafold":{"accession":"P20674","domains":[{"cath_id":"1.25.40.40","chopping":"51-146","consensus_level":"high","plddt":98.3441,"start":51,"end":146}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P20674","model_url":"https://alphafold.ebi.ac.uk/files/AF-P20674-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P20674-F1-predicted_aligned_error_v6.png","plddt_mean":87.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=COX5A","jax_strain_url":"https://www.jax.org/strain/search?query=COX5A"},"sequence":{"accession":"P20674","fasta_url":"https://rest.uniprot.org/uniprotkb/P20674.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P20674/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P20674"}},"corpus_meta":[{"pmid":"28247525","id":"PMC_28247525","title":"Mutation in mitochondrial complex IV subunit COX5A causes pulmonary arterial hypertension, lactic acidemia, and failure to thrive.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/28247525","citation_count":37,"is_preprint":false},{"pmid":"31258460","id":"PMC_31258460","title":"The Dual Role of AQP4 in Cytotoxic and Vasogenic Edema Following Spinal Cord Contusion and Its Possible Association With Energy Metabolism via COX5A.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31258460","citation_count":34,"is_preprint":false},{"pmid":"37373547","id":"PMC_37373547","title":"COX5A Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress, Mitochondrial Dysfunction and Cardiomyocyte Apoptosis.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37373547","citation_count":30,"is_preprint":false},{"pmid":"32754029","id":"PMC_32754029","title":"COX5A Plays a Vital Role in Memory Impairment Associated With Brain Aging via the BDNF/ERK1/2 Signaling Pathway.","date":"2020","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32754029","citation_count":25,"is_preprint":false},{"pmid":"25575679","id":"PMC_25575679","title":"Sodium Channel Voltage-Gated Beta 2 Plays a Vital Role in Brain Aging Associated with Synaptic Plasticity and Expression of COX5A and FGF-2.","date":"2015","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25575679","citation_count":21,"is_preprint":false},{"pmid":"25436770","id":"PMC_25436770","title":"Hypermethylation of Cox5a promoter is associated with mitochondrial dysfunction in skeletal muscle of high fat diet-induced insulin resistant rats.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25436770","citation_count":18,"is_preprint":false},{"pmid":"32349668","id":"PMC_32349668","title":"COX5A over-expression protects cortical neurons from hypoxic ischemic injury in neonatal rats associated with TPI up-regulation.","date":"2020","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32349668","citation_count":17,"is_preprint":false},{"pmid":"32758616","id":"PMC_32758616","title":"miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32758616","citation_count":16,"is_preprint":false},{"pmid":"37007963","id":"PMC_37007963","title":"CLPP inhibition triggers apoptosis in human ovarian granulosa cells via COX5A abnormality-Mediated mitochondrial dysfunction.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37007963","citation_count":10,"is_preprint":false},{"pmid":"36924093","id":"PMC_36924093","title":"Protective Role of Cytochrome C Oxidase 5A (COX5A) against Mitochondrial Disorder and Oxidative Stress in VSMC Phenotypic Modulation and Neointima Formation.","date":"2023","source":"Current vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36924093","citation_count":9,"is_preprint":false},{"pmid":"35246835","id":"PMC_35246835","title":"A novel homozygous variant in COX5A causes an attenuated phenotype with failure to thrive, lactic acidosis, hypoglycemia, and short stature.","date":"2022","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35246835","citation_count":7,"is_preprint":false},{"pmid":"38416461","id":"PMC_38416461","title":"Hydrogen peroxide sensitivity connects the activity of COX5A and NPR3 to the regulation of YAP1 expression.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38416461","citation_count":6,"is_preprint":false},{"pmid":"37891386","id":"PMC_37891386","title":"COX5A as a potential biomarker for disease activity and organ damage in lupus.","date":"2023","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37891386","citation_count":1,"is_preprint":false},{"pmid":"41842984","id":"PMC_41842984","title":"COX5A induces M2 macrophage polarization in chronic rhinosinusitis with nasal polyps through ROS generation.","date":"2026","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/41842984","citation_count":0,"is_preprint":false},{"pmid":"41184196","id":"PMC_41184196","title":"Cytochrome c Oxidase Subunit 5A (COX5A) Enhances Gastric Cancer Progression by Augmenting ATP Synthesis and Activating the PI3K/Akt Pathway.","date":"2025","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41184196","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.01.679889","title":"Association of cytochrome c oxidase dysfunction with amyloidosis in Alzheimer’s disease and patient-derived cerebral organoids","date":"2025-10-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.01.679889","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10541,"output_tokens":3329,"usd":0.040779,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10961,"output_tokens":3709,"usd":0.073765,"stage2_stop_reason":"end_turn"},"total_usd":0.114544,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"A pathogenic variant in COX5A lying within the COX5A/COX4 interface domain reduces complex IV enzymatic activity and protein levels, causes accumulation of the monomeric COX1 assembly intermediate, and disrupts complex IV biogenesis; lentiviral complementation rescues the deficiency, and copper supplementation partially rescues complex IV activity in patient fibroblasts.\",\n      \"method\": \"Patient fibroblast biochemical assays, lentiviral complementation, structural homology modeling of the COX5A/COX4 interface, copper supplementation rescue experiment\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal protein-level and enzymatic assays in patient cells, lentiviral rescue, assembly intermediate detection, replicated by a second family report (PMID:35246835)\",\n      \"pmids\": [\"28247525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A second homozygous missense variant (c.266T>G) in COX5A reduces COX5A protein level and complex IV (COX) activity, confirming that biallelic loss-of-function variants in COX5A cause mitochondrial disease with complex IV deficiency.\",\n      \"method\": \"Clinical exome sequencing, western blotting for COX5A protein, enzymatic assay of COX activity in patient-derived cells\",\n      \"journal\": \"Clinical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic and protein-level assays in patient cells, single lab, corroborates prior report\",\n      \"pmids\": [\"35246835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Hypermethylation of the Cox5a promoter in skeletal muscle of high-fat diet rats is associated with reduced Cox5a mRNA and protein, decreased mitochondrial complex IV activity, and lower ATP content; demethylation with 5-aza-2'-deoxycytidine in palmitate-treated myotubes preserves Cox5a expression and restores complex IV activity and ATP levels.\",\n      \"method\": \"Whole-genome promoter methylation analysis, bisulfite sequencing, qPCR, western blot, complex IV activity assay, ATP measurement, 5-aza-2'-deoxycytidine demethylation experiment in rat myotubes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (methylation sequencing, expression, enzymatic assay, pharmacological rescue), single lab\",\n      \"pmids\": [\"25436770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"COX5A overexpression in transgenic mice improves spatial recognition memory and hippocampal synaptic plasticity and activates the BDNF/ERK1/2 signaling pathway; combined COX5A overexpression with BDNF knockdown abrogates these benefits, placing COX5A upstream of BDNF/ERK1/2 in neuronal function.\",\n      \"method\": \"COX5A transgenic mice, BDNF knockdown mice, Morris water maze/spatial memory testing, LTP measurement, dendritic morphology analysis, western blot for BDNF/ERK1/2 pathway components, in vitro neuronal growth assays\",\n      \"journal\": \"Frontiers in aging neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (double transgenic), multiple behavioral and cellular readouts, single lab\",\n      \"pmids\": [\"32754029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"COX5A overexpression in cortical neurons after oxygen-glucose deprivation promotes neuronal survival, reduces apoptosis, increases neurite length, and upregulates Triosephosphate isomerase (TPI); TPI was identified as a physical interaction partner of COX5A by network prediction and validated by western blot.\",\n      \"method\": \"HSV-mediated COX5A overexpression in OGD neurons, TUNEL/immunofluorescence, western blot, qRT-PCR, GeneMANIA interaction prediction followed by WB validation\",\n      \"journal\": \"BMC neuroscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — TPI interaction validated by WB only after computational prediction, single lab, no direct binding assay\",\n      \"pmids\": [\"32349668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"COX5A overexpression in DOX-treated cardiomyocytes and mice restores cytochrome c oxidase activity, ATP content, and mitochondrial morphology, reduces oxidative stress and apoptosis, and activates PI3K/Akt signaling (phosphorylation of Akt Thr308 and Ser473); PI3K inhibitors abrogate the protective effects, placing COX5A upstream of PI3K/Akt.\",\n      \"method\": \"AAV9/lentivirus-mediated COX5A overexpression in mice and H9c2 cells, echocardiography, transmission electron microscopy, immunofluorescence, COX activity assay, ATP measurement, western blot for PI3K/Akt pathway, PI3K inhibitor rescue experiment\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in vivo and in vitro with pathway inhibitor rescue, single lab\",\n      \"pmids\": [\"37373547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CLPP inhibition causes accumulation of aggregated/misfolded COX5A, reducing complex IV (oxidative respiratory chain complex IV) content and activity, which leads to ROS accumulation, loss of mitochondrial membrane potential, and activation of the intrinsic apoptotic pathway in human ovarian granulosa cells.\",\n      \"method\": \"CLPP inhibitor treatment, COX5A overexpression/knockdown in granulosa cells, complex IV activity assay, ROS measurement, mitochondrial membrane potential assay, flow cytometry for apoptosis\",\n      \"journal\": \"Frontiers in genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assays with multiple orthogonal readouts in relevant human cell line, single lab\",\n      \"pmids\": [\"37007963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"COX5A overexpression in vascular smooth muscle cells (VSMCs) restores PDGF-BB-impaired complex IV activity, oxygen consumption rate, and ATP synthesis while reducing H2O2/ROS production and inhibiting VSMC proliferation and migration; in vivo lentiviral COX5A overexpression attenuates balloon injury-induced neointima formation and mitochondrial ultrastructural damage.\",\n      \"method\": \"pcDNA3.1-COX5A overexpression and siRNA knockdown in HA-VSMCs, complex IV activity assay, oxygen consumption rate (Seahorse), H2O2/ATP/ROS measurements, cell proliferation/migration assays, lentiviral delivery in rat balloon injury model, carotid morphology and TEM analysis\",\n      \"journal\": \"Current vascular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo methods, single lab\",\n      \"pmids\": [\"36924093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Knockdown of SCN2B in transgenic mice upregulates COX5A mRNA levels and improves hippocampus-dependent spatial memory and LTP, suggesting SCN2B negatively regulates COX5A expression in the context of brain aging.\",\n      \"method\": \"SCN2B knockdown transgenic mice, Morris water maze, LTP (fEPSP) electrophysiology, qPCR for COX5A mRNA\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — COX5A measured only as mRNA readout in SCN2B-knockdown model, no direct mechanistic interrogation of COX5A, single lab\",\n      \"pmids\": [\"25575679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-204 directly targets and suppresses COX5A expression in ER-positive breast cancer cells; COX5A knockdown decreases ERα expression, causes cell cycle arrest, blocks epithelial-mesenchymal transition, reduces ATP, and increases ROS, thereby inhibiting proliferation, invasion, and enhancing chemosensitivity.\",\n      \"method\": \"miR-204 overexpression targeting COX5A (in vitro), siRNA knockdown of COX5A in ER+ breast cancer cell lines, ERα western blot, cell cycle flow cytometry, EMT marker analysis, ATP and ROS measurement\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple functional readouts after COX5A manipulation plus miRNA targeting validation, single lab\",\n      \"pmids\": [\"32758616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In yeast, deletion of COX5A causes hypersensitivity to H2O2; COX5A and NPR3 regulate YAP1 (oxidative stress transcription factor) expression through an alternative mode of translation initiation, linking COX5A to oxidative stress detoxification and antioxidant gene regulation.\",\n      \"method\": \"Yeast deletion strains, H2O2 sensitivity assays, YAP1 expression analysis, genetic epistasis, translation initiation reporter assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast model, single lab, novel mechanism of YAP1 regulation via alternative translation initiation not yet validated in mammalian system\",\n      \"pmids\": [\"38416461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"COX5A knockdown in IL-13-stimulated nasal epithelial cells abolishes ROS production and prevents M2 macrophage polarization; COX5A-mediated ROS generation in epithelial cells drives M2 macrophage polarization, and this pathway is confirmed elevated in a murine nasal polyp model.\",\n      \"method\": \"COX5A siRNA knockdown in IL-13-stimulated epithelial cells, ROS scavenger experiments, flow cytometry for macrophage polarization markers, western blotting, immunofluorescence, murine nasal polyp in vivo model\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — COX5A knockdown with ROS scavenger controls, in vitro and in vivo concordance, single lab\",\n      \"pmids\": [\"41842984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"COX5A enhances mitochondrial oxidative phosphorylation and ATP production in gastric cancer cells, and the resulting elevated ATP activates PI3K/Akt signaling to drive proliferation, migration, and invasion; COX5A silencing suppresses xenograft tumor growth, and PI3K/Akt inhibitors reverse COX5A-mediated effects.\",\n      \"method\": \"COX5A overexpression/silencing in gastric cancer cell lines, JC-1 mitochondrial membrane potential assay, ATP measurement, western blot for PI3K/Akt, PI3K inhibitor rescue, xenograft mouse model\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in vitro and in vivo with pathway inhibitor rescue, single lab\",\n      \"pmids\": [\"41184196\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"COX5A is a nuclear-encoded structural subunit of mitochondrial respiratory chain complex IV (cytochrome c oxidase) that is required for complex IV biogenesis (acting at the COX5A/COX4 interface) and catalytic activity; loss-of-function causes complex IV deficiency, impaired oxidative phosphorylation, reduced ATP synthesis, and excess ROS, while COX5A overexpression or rescue restores these functions and activates downstream PI3K/Akt and BDNF/ERK1/2 signaling pathways in cardiac, neuronal, vascular, and cancer contexts.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"COX5A is a nuclear-encoded structural subunit of mitochondrial respiratory chain complex IV (cytochrome c oxidase) required for complex IV biogenesis and catalytic activity [#0]. A pathogenic variant within the COX5A/COX4 interface domain reduces complex IV enzymatic activity and protein levels, causes accumulation of the monomeric COX1 assembly intermediate, and disrupts complex IV assembly, with lentiviral complementation and copper supplementation rescuing the deficiency; a second biallelic missense variant independently confirms that loss-of-function in COX5A causes mitochondrial disease with complex IV deficiency [#0, #1]. Consistent with this catalytic role, conditions that lower COX5A — promoter hypermethylation, miR-204 targeting, or CLPP-driven misfolding — reduce complex IV activity, ATP content, and mitochondrial membrane potential while elevating ROS, and these are reversed by restoring COX5A expression [#2, #6, #9]. Across cardiac, vascular, neuronal, and cancer contexts, COX5A acts upstream of growth and survival signaling: its overexpression restores cytochrome c oxidase activity and ATP and activates PI3K/Akt signaling to support cardiomyocyte protection, attenuate vascular neointima formation, and drive gastric cancer proliferation and invasion [#5, #7, #12], and it activates BDNF/ERK1/2 signaling to enhance hippocampal synaptic plasticity and spatial memory [#3]. COX5A-dependent mitochondrial ROS generation also functions as a signaling output, driving M2 macrophage polarization in IL-13-stimulated nasal epithelium [#11].\",\n  \"teleology\": [\n    {\n      \"year\": 2017,\n      \"claim\": \"Established that COX5A is a structural subunit essential for complex IV biogenesis and that a human variant at the COX5A/COX4 interface causes complex IV deficiency, defining its disease-causing mechanism.\",\n      \"evidence\": \"Patient fibroblast enzymatic and protein assays, lentiviral complementation, assembly-intermediate detection, and copper supplementation rescue\",\n      \"pmids\": [\"28247525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of the human COX5A/COX4 interface within assembled complex IV\", \"Mechanism by which copper supplementation partially rescues activity not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed that biallelic loss-of-function variants in COX5A cause mitochondrial disease, generalizing the genotype-phenotype link beyond a single family.\",\n      \"evidence\": \"Clinical exome sequencing with COX5A western blot and COX enzymatic assay in patient cells\",\n      \"pmids\": [\"35246835\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab corroboration\", \"No functional rescue performed for this variant\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed that COX5A expression is epigenetically regulated and that its loss is sufficient to impair complex IV activity and ATP production, linking metabolic stress to COX5A silencing.\",\n      \"evidence\": \"Promoter methylation sequencing, expression analysis, complex IV/ATP assays, and 5-aza-deoxycytidine demethylation rescue in high-fat-diet rat muscle and palmitate-treated myotubes\",\n      \"pmids\": [\"25436770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Rodent/cell model only\", \"Transcription factors mediating methylation-dependent silencing not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed COX5A upstream of BDNF/ERK1/2 signaling in neuronal function, indicating a signaling role beyond bioenergetics in cognition.\",\n      \"evidence\": \"COX5A transgenic and BDNF-knockdown mice with spatial memory, LTP, dendritic morphology, and pathway western blots\",\n      \"pmids\": [\"32754029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between mitochondrial COX5A and BDNF transcription unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified TPI as a candidate COX5A interaction partner and a neuroprotective effector after ischemic stress.\",\n      \"evidence\": \"HSV-mediated COX5A overexpression in OGD neurons, computational interaction prediction, and western blot validation\",\n      \"pmids\": [\"32349668\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"TPI interaction shown by WB only after computational prediction, no direct binding assay\", \"No reciprocal validation\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that COX5A is a direct miR-204 target and that its loss in ER+ breast cancer suppresses proliferation, EMT, and ERα, connecting COX5A regulation to oncogenic phenotypes.\",\n      \"evidence\": \"miR-204 targeting, COX5A siRNA, cell cycle, EMT marker, ATP, and ROS analyses in ER+ breast cancer cells\",\n      \"pmids\": [\"32758616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking COX5A to ERα expression undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established COX5A as a protective factor upstream of PI3K/Akt in doxorubicin cardiotoxicity, restoring complex IV activity, ATP, and mitochondrial morphology.\",\n      \"evidence\": \"AAV9/lentiviral COX5A overexpression in mice and H9c2 cells with COX/ATP assays, TEM, and PI3K inhibitor rescue\",\n      \"pmids\": [\"37373547\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link from complex IV/ATP to Akt phosphorylation not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed COX5A overexpression restores mitochondrial function in vascular smooth muscle cells and limits neointima formation, extending its protective role to vascular injury.\",\n      \"evidence\": \"COX5A overexpression/knockdown in HA-VSMCs with Seahorse, COX/ATP/ROS assays, proliferation/migration assays, and rat balloon injury model\",\n      \"pmids\": [\"36924093\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway downstream of restored mitochondrial function in VSMCs not delineated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined COX5A as a target of CLPP-dependent proteostasis whose misfolding/aggregation drives complex IV loss, ROS, and intrinsic apoptosis.\",\n      \"evidence\": \"CLPP inhibition plus COX5A overexpression/knockdown in human ovarian granulosa cells with complex IV, ROS, membrane potential, and apoptosis assays\",\n      \"pmids\": [\"37007963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CLPP directly processes COX5A not shown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Proposed a non-canonical role for COX5A in oxidative stress detoxification via YAP1 regulation through alternative translation initiation in yeast.\",\n      \"evidence\": \"Yeast deletion strains, H2O2 sensitivity, YAP1 expression, epistasis, and translation initiation reporters\",\n      \"pmids\": [\"38416461\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Yeast model only, not validated in mammalian cells\", \"Mechanism of alternative translation initiation regulation unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed COX5A-driven OXPHOS and ATP activate PI3K/Akt to promote gastric cancer growth, establishing a pro-tumorigenic bioenergetic-signaling axis.\",\n      \"evidence\": \"COX5A overexpression/silencing in gastric cancer lines with JC-1, ATP assays, PI3K/Akt western blot, inhibitor rescue, and xenografts\",\n      \"pmids\": [\"41184196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular coupling of ATP levels to PI3K/Akt activation undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrated that COX5A-dependent mitochondrial ROS in nasal epithelium drives M2 macrophage polarization, framing COX5A output as an inflammatory signaling source.\",\n      \"evidence\": \"COX5A siRNA in IL-13-stimulated epithelial cells with ROS scavenger controls, macrophage polarization flow cytometry, and murine nasal polyp model\",\n      \"pmids\": [\"41842984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Soluble or contact mediators of epithelium-to-macrophage signaling not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How COX5A bioenergetic output is mechanistically transduced into discrete downstream signaling programs (PI3K/Akt, BDNF/ERK1/2, ROS-driven inflammation) across tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct molecular link established between complex IV activity/ATP/ROS and the activated kinase cascades\", \"Whether signaling effects are tissue-specific or generalizable is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 5, 6, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 5, 7, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 12]}\n    ],\n    \"complexes\": [\"cytochrome c oxidase (complex IV)\"],\n    \"partners\": [\"COX4\", \"COX1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}